[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571461":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":33,"locations":39,"responsibleParty":54,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Catholic University of the Sacred Heart","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Deceptive Placebo","EXPERIMENTAL",null,[13],"Other: Placebo probiotic",{"label":15,"type":6,"description":16,"interventionNames":17},"Control - Open-Label PLacebo","The Control Arm will not be exposed to any intervention for the first three weeks. After this time and for the following three weeks, participants will receive placebo probiotic pills in an open-label fashion: they will be honestly informed that the pills are inert placebos.",[18,19],"Other: Open-Label Placebo probiotic","Other: Control-no treatment",[21,25,29],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"Placebo probiotic","Three-week consumption of placebo probiotic capsules passed off as being actual probiotics",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Open-Label Placebo probiotic","Participants of the Control group will be switched to this condition after three weeks and receive placebo probiotic capsules for the following three-weeks of no intervention. Specifically, they will be honestly informed that the capsules are inert placebos.",[15],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Control-no treatment","For the first three weeks, the Control group will not be exposed to any intervention.",[15],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Diletta Barbiani","CONTACT","+393338059338","diletta.barbiani@unicatt.it",[40],{"facility":5,"status":41,"city":42,"state":11,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Milan","20123","Italy","IT",{"type":47,"coordinates":48},"Point",[49,50],9.18951,45.46427,{"lat":50,"lon":49},[53],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},{"type":55,"investigatorFullName":35,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Junior Assistant Professor","100571461","effects-of-a-placebo-probiotic-on-gut-health-and-general-well-being-in-individuals-with-mild-gastrointestinal-symptoms-100571461",false,"NCT06720558","Effects of a Placebo Probiotic on Gut Health and General Well-being in Individuals With Mild Gastrointestinal Symptoms","A 3-week Randomized Controlled Trial on the Efficacy of a Placebo Probiotic in Rebalancing Gut Health and Fostering Physical and Emotional Well-being in Individuals With Mild Gastrointestinal Symptoms","PlaCIBO","Inclusion Criteria:\n\n* Age between 20 and 65\n* Individuals with mild gastrointestinal symptoms (e.g., digestive issues, acid reflux, constipation) such that normal every-day activities are not severly compromised.\n\nExclusion Criteria:\n\n* Individuals with a diagnosis of functional gastrointestinal disorders (e.g., irritable bowel syndrome, ulcerative colitis, chronic inflammatory bowel diseases).\n* Individuals suffering from neurodegenerative diseases and\u002For psychiatric conditions\n* Individuals taking probiotic supplementation at the time of enrollment in the study",true,"ALL","20 Years","65 Years",{"count":70,"type":71},30,"ESTIMATED","INTERVENTIONAL",[74],"NA","The present study is aimed at exploring whether positive expectations of receiving a three-week treatment with a probiotic supplement (in fact a placebo) improve symptoms of gastrointestinal distress and promote physical and emotional well-being in healthy individuals with mild gastrointestinal symptoms. At first, a comparison is planned between (1) a classic deceptive placebo manipulation (Deceptive Placebo group, DP), and (2) a control condition (Control group, C), in which no placebo substance will be administered. After the three-week waiting list, the Control group will be invited to take the placebo probiotic pills in an \"open-label\" fashion (Open Label Placebo, OLP). Specifically, participants will be informed that the pills are inert placebos. An exploratory analysis will help to clarify whether the OLP paradigm leads to significant effects, based on a within-group (C- OLP) and between-group comparison (DP-OLP).",[77],"Healthy",[79,80,81],"Gastrointestinal Symptoms","Placebo Effect","Open-Label Placebo","2024-12-02",{"date":84,"type":85},"2024-12-06","ACTUAL",{"date":87,"type":85},"2024-11-20",{"date":89,"type":71},"2025-04",{"name":5,"class":6},1]